Financials in USD. Standardized financial statements.
A compact view of how Regen BioPharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $236,561 | $236,560 | $236,560 | $235,517 | $171,194 | $110,000 | $110,000 | $100,000 | $110,000 | $100,000 |
| Revenue Growth? | +0.0% | 0.0% | +0.4% | +37.6% | +55.6% | 0.0% | +10.0% | -9.1% | +10.0% | 0.0% |
| Cost of Revenue? | $0 | $77,215 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $236,561 | $236,560 | $236,560 | $185,517 | $146,194 | $110,000 | $110,000 | $100,000 | $110,000 | $100,000 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +78.8% | +85.4% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $575,101 | $653,781 | $923,510 | $575,122 | $346,965 | $319,317 | $866,785 | $1.53M | $2.62M | $3.06M |
| Operating Income? | -$338,540 | -$417,000 | -$687,000 | -$340,000 | -$201,000 | -$209,000 | -$757,000 | -$1.43M | -$2.51M | -$2.96M |
| EBITDA? | -$338,540 | -$418,000 | $3.12M | $2.99M | -$6.20M | $4.57M | -$46,094 | -$3.15M | -$2.46M | -$3.37M |
| Income Before Tax | -$1.27M | -$668,000 | $1.16M | $2.44M | -$6.76M | $3.41M | -$2.62M | -$4.71M | -$5.84M | -$3.41M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$1.27M | -$668,000 | $1.02M | $2.23M | -$6.76M | $2.73M | -$2.62M | -$4.71M | -$5.84M | -$3.41M |
| EPS? | $-0.05 | $-0.16 | $0.14 | $0.36 | $-1.69 | $1.90 | $-1.95 | $-46.50 | $-61.93 | $-40.05 |
| Diluted EPS? | $-0.05 | $-0.16 | $0.14 | $0.36 | $-1.69 | $1.90 | $-1.95 | $-46.50 | $-61.93 | $-40.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality